載入中
NASDAQHealthcareBiotechnology
最新資料
US$16.53
+US$1.39 · +9.18%
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
前收盤價
US$16.53
+US$1.39 · +9.18%
盤中時間採用ET。市場資料可能有所延遲。
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
日內區間
目前US$16.53
52週區間
目前US$16.53
盤中時間採用ET。市場資料可能有所延遲。
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
日內區間
目前US$16.53
52週區間
目前US$16.53
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 1779 USD | 3612 USD | 3612 USD | 3612 USD | 3612 USD |
| 毛利 | −1779 USD | −3612 USD | −3612 USD | −3612 USD | −3612 USD |
| 研究與開發 | 1722.04萬 USD | 1548.02萬 USD | 769.86萬 USD | 647.57萬 USD | 355.95萬 USD |
| 銷售、一般及管理費用 | 222.57萬 USD | 215.34萬 USD | 162.92萬 USD | 156.46萬 USD | 103.84萬 USD |
| 營業費用 | 1944.61萬 USD | 1763.36萬 USD | 932.43萬 USD | 803.66萬 USD | 459.43萬 USD |
| 利息收入 | 8.97萬 USD | 22.3萬 USD | 43.61萬 USD | 21.5萬 USD | 2.74萬 USD |
| 折舊和攤銷 | 1779 USD | 3612 USD | 3612 USD | 3612 USD | 3612 USD |
| 營業利益 | −1944.79萬 USD | −1763.72萬 USD | −932.79萬 USD | −804.03萬 USD | −459.79萬 USD |
| 淨利 | −1935.82萬 USD | −1741.42萬 USD | −889.18萬 USD | −782.52萬 USD | −457.06萬 USD |
公司資料更新於 2026年10月12日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM309.3萬0.00%787.4億 USD0.19%US$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI297.53萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 Growth ETFIWO108.96萬0.01%139.17億 USD0.24%US$356.78+0.94%
Vanguard Extended Market ETFVXF108.04萬0.00%954億 USD0.05%US$235+0.80%
Vanguard U.S. Momentum Factor ETFVFMO80.4萬0.04%19億 USD0.13%US$230.11+1.02%
Vanguard Russell 2000 ETFVTWO57.75萬0.00%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC37.25萬0.03%13.17億 USD0.60%US$183+0.11%
Vanguard Russell 2000 Growth ETFVTWG11.21萬0.01%17億 USD0.06%US$260.49+0.91%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFVanguard U.S. Momentum Factor ETFVFMOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
